Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Dicerna to Participate in the Chardan 4th Annual Genetic Medicines Conference


Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Mon., Oct. 5, 2020 at 1:30 p.m. ET.

A live audio webcast of the event will be accessible from the Investors and Media section of the Dicerna website at www.investors.dicerna.com. An archived replay will be available on the Company's website following the event.

About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. Using our proprietary RNAi technology platform called GalXCtm, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on hepatocytes, Dicerna has continued to innovate and is exploring new applications of its RNAi technology beyond the liver, targeting additional tissues and enabling new therapeutic applications. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegeneration and pain. At Dicerna, our mission is to interfere ? to silence genes, to fight disease, to restore heath. For more information, please visit www.dicerna.com.

Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements relating to the Company's planned attendance at an investor conference, which may include discussion of the Company's business, plans and research and development. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those risks identified under the heading "Risk Factors" included in our most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

GalXCtm is a trademark of Dicerna Pharmaceuticals, Inc.


These press releases may also interest you

at 15:05
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual...

at 15:01
G FUEL and Gearbox Entertainment Company celebrate gaming icon Duke Nukem with Ego Boost, a new zero-sugar Energy Formula now available at GFUEL.com. Fans can purchase the cherry, orange, and pomegranate flavor as a 40-serving standalone powder Tub...

at 15:00
Beghou Consulting announced Thursday several additions to its executive team to support the company's technology innovation, product development and growth initiatives. Dan Cardinal, a Partner at Beghou, will become Chief Technology Officer. The...

at 15:00
Certified BERNINA dealer, Hoover's BERNINA Sew LLC, is thrilled to announce the return of their annual Spring Fling event. Taking place April 10th through April 12th at The Rusty Rail, the event offers giveaways, door prizes, and the opportunity to...

at 15:00
General Dynamics Information Technology (GDIT), a business unit of General Dynamics , announced today that it was awarded a $922 million contract to modernize the U.S. Central Command's (CENTCOM) enterprise IT infrastructure. The new contract,...

at 15:00
O'Sewpersonal, an authorized BERNINA dealer, is thrilled to announce Stitchfest 2024. The sewing, embroidery, and quilting event will be taking place from Thursday, April 11th through Saturday, April 13th, 2024 at the St. Louis West Marriott. Kelly...



News published on and distributed by: